Targeted treatment for driving oncogenic mutations has significantly improved outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC) as well. A case study was recently published in the journal Frontiers in Oncology of a patient with advanced disease who achieved complete remission after several lines of therapy.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
